Innate Pharma S.A. Depositary Receipt Price Target Increased by 29.10% to $7.36

Innate Pharma's average one-year price target has been revised to $7.36/share, a 29.10% increase from the prior estimate of $5.70/share. This is based on the average of many targets provided by analysts, ranging from $7.22 to $7.63/share. The price target represents a 306.42% increase from the latest reported closing price of $1.81/share. There are 9 funds or institutions reporting positions in Innate Pharma, with an average portfolio weight of 0.00% and total shares owned by institutions decreasing by 53.08% to 80K shares in the last three months.